Johnson & Johnson has warned that it may stop supplying free medicines through early access schemes in Britain because of a dispute over VAT enforcement by HM Revenue & Customs.
The issue affects medicines provided at no cost to patients through compassionate use or post-clinical trial programs. These schemes can help patients access innovative treatments before full reimbursement or broader market access is available.
Free Medicines Become a Tax Risk
The dispute is sensitive because the medicines are supplied free of charge, often to patients with serious or life-threatening conditions.
Johnson & Johnson has argued that enforcing backdated VAT on these medicines could threaten future access to innovative treatments, although the company has said it will continue supporting current patients.
The core issue is whether a tax liability could make compassionate access programs commercially harder to sustain.
Other companies have also raised concerns, and the issue has drawn attention from charities, lawmakers and the pharmaceutical industry.
Clinical Access and Life Sciences Policy Collide
For the UK, the dispute comes at a difficult moment. The country wants to strengthen its life sciences position, attract clinical research and improve patient access to advanced medicines.
But uncertainty around tax treatment may make companies more cautious about offering free post-trial or early access medicines.
For pharma companies, policy clarity matters as much as headline market access.
If unresolved, the VAT issue could affect how companies design compassionate access programs, clinical trial continuation support and patient access strategies in Britain.
For patients, the risk is direct: fewer free access routes could delay treatment options when standard reimbursement pathways are not yet available.
